The FDA has released a safety communication alerting healthcare providers to a new risk evaluation and mitigation strategy for ipilimumab.
On April 6, 2011, FDA released a safety communication alerting healthcare providers to a new risk evaluation and mitigation strategy (REMS) for ipilimumab (Yervoy, Bristol-Myers Squibb).
The currently available prescribing information for ipilimumab contains a black-boxed warning stating that use of the product can result in severe and fatal immune-mediated adverse reactions.
According to FDA, the ipilimumab REMS will consist of a communication plan to inform healthcare professionals of the serious risks of ipilimumab in order to facilitate early identification of these risks, and recommendations for management of patients with moderate or severe immune-mediated adverse reactions including enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.
According to the drug's prescribing information and FDA release, immune-mediated hepatitis and endocrinopathies should be monitored prior to each dose of ipilimumab. If a severe case of immune-mediated reaction occurs, ipilimumab should be permanently discontinued. For moderate immune-mediated adverse reactions, it is recommended that ipilimumab be withheld until the patient returns to baseline, the reaction improves to a mild severity or complete resolution is achieved, and patient is receiving <7.5 mg prednisone or equivalent per day. High-dose systemic corticosteroids are recommended for patients experiencing a severe, persistent, or recurring immune-mediated reaction.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More